Study Overview
This study looked at a new type of medication called potassium-competitive acid blockers (P-CABs), specifically fexuprazan, to see how well it works for people with chronic cough related to gastroesophageal reflux disease (GERD).
Study Details
In this trial, adults with a chronic cough lasting at least 8 weeks and a recent diagnosis of GERD were treated with either fexuprazan or esomeprazole (a common acid suppressor) for 8 weeks. The main goal was to see how much their cough improved, measured by a specific questionnaire.
Results
Out of 190 people who started the study, 146 completed it. Most participants were women, averaging 39 years old. After 8 weeks, both medications showed similar improvements in cough-related quality of life. The side effects were mostly mild and similar for both medications.
Conclusions
The results suggest that P-CABs like fexuprazan could be a good alternative to traditional medications for treating chronic cough in GERD patients.
Practical Healthcare Solutions
Measurable Outcomes
Clinics should aim for clear goals such as improving cough quality of life and reducing cough severity in GERD patients using P-CABs.
AI Tools for Clinical Needs
Select AI solutions tailored for tracking patient outcomes and managing treatments effectively.
Implementation Steps
Start with a pilot project to test the use of P-CABs and track results. Use AI tools to analyze the real-world impact of these treatments.
Contact Us
For more information on AI solutions in medical management, reach out via:
